Involving medical companions in an explanation about switching to a biosimilar.

Not Applicable

Completed

• Conditions: Patients taking biologic medications (e.g. adalimumab, etanercept, infliximab, rituximab, tocilizumab) for rheumatic diseases.; Patients taking biologic medications (e.g. adalimumab, etanercept, infliximab, rituximab, tocilizumab) for dermatological diseases.; Decision making; Inflammatory and Immune System - Rheumatoid arthritis; Skin - Dermatological conditions; Public Health - Health service research

• Registration Number: ACTRN12619001435178
• Lead Sponsor: Professor Keith Petrie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-10-16
• Study Completion: 2020-11-24
• Last Update Posted: 10 May 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 79

Inclusion Criteria

Patients are eligible to participate if they:
- are attending an appointment with their rheumatologist/dermatologist at a clinic across the Auckland and Waitemata District Health Board,
- are 18 years of age or over,
- take a biologic medication (e.g., adalimumab, etanercept, infliximab, rituximab, tocilizumab),
- have a companion (support person) that is 18 years of age or over.

Exclusion Criteria

Participants will be excluded from this study if they:
- are unable to fill out the questionnaires,
- cannot understand, read or write English.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients' willingness to switch from a biologic drug to a biosimilar assessed using a dichotomous scale (yes/no).[Immediately post-intervention]